GlassScriptPhysician profile
Adrian Wong
NPI 1487909867
$2,888.60
in general payments reported to CMS, 2019-2025
28 companies · $733 in 2025
The $733 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $83.54 · 2020: $62.50 · 2021: $132 · 2022: $344 · 2023: $833 · 2024: $700 · 2025: $733.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,266.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,266.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $784.48 | 2019-2025 | Farxiga, Lokelma |
| Mallinckrodt Hospital Products INC. | $247.80 | 2020-2023 | Acthar, Terlivaz |
| Opko Pharmaceuticals, LLC | $225.31 | 2021-2025 | Rayaldee |
| Novartis Pharmaceuticals Corporation | $188.19 | 2024-2025 | |
| Cormedix INC. | $156.36 | 2024-2025 | Defencath, Defencath |
| Lilly USA, LLC | $153.36 | 2024-2025 | Jardiance |
| Medtronic, INC. | $149.92 | 2023 | Cardiosight Reader |
| Horizon Therapeutics Plc | $114.60 | 2021-2022 | |
| Aurinia Pharma U.S., INC. | $101.48 | 2023-2024 | Lupkynis |
| Glaxosmithkline, LLC. | $87.09 | 2022-2023 | Benlysta |
| Travere Therapeutics, INC. | $80.74 | 2023-2025 | |
| Amgen INC. | $75.16 | 2025 | Tavneos, Krystexxa |
| Novo Nordisk INC | $67.94 | 2025 | Wegovy |
| Alexion Pharmaceuticals, INC. | $61.80 | 2021-2024 | Ultomiris |
| Ardelyx, INC. | $59.70 | 2024-2025 | Ibsrela |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $43.56 | 2024-2025 | |
| Daiichi Sankyo INC. | $39.61 | 2020-2023 | Injectafer |
| Fresenius USA Marketing, INC. | $36.10 | 2022 | |
| Ani Pharmaceuticals, INC. | $30.98 | 2024-2025 | Purified Cortrophin Gel |
| Veloxis Pharmaceuticals, INC. | $28.30 | 2024 | Envarsus |
| Akebia Therapeutics INC | $26.13 | 2023 | Auryxia |
| Abbvie INC. | $25.12 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.82 | 2023 | Jardiance, Tradjenta |
| Takeda Pharmaceuticals U.S.A., INC. | $19.28 | 2022 | |
| Kyowa Kirin, INC. | $18.67 | 2024 | Crysvita |
| Genzyme Corporation | $16.28 | 2025 | |
| Scpharmaceuticals INC. | $15.16 | 2025 | |
| Vifor Pharma, INC. | $13.66 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adrian Wong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.